NMDAR

Gate Neurosciences Announces Clinical Collaboration with Beacon Biosignals to Advance Precision EEG Biomarkers in Major Depressive Disorder

Retrieved on: 
Wednesday, January 24, 2024

Gate Neurosciences , a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced a strategic collaboration with Beacon Biosignals to further advance the use of electroencephalogram (EEG) biomarkers across the company’s clinical pipeline in neuropsychiatry and cognition.

Key Points: 
  • Gate Neurosciences , a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced a strategic collaboration with Beacon Biosignals to further advance the use of electroencephalogram (EEG) biomarkers across the company’s clinical pipeline in neuropsychiatry and cognition.
  • Zelquistinel is a rapid-acting, once-weekly oral NMDA receptor positive modulator in development for treating major depressive disorder (MDD).
  • “The Gate team is excited to partner with Beacon in pioneering a new era of precision psychiatry with innovative biomarker insights, approaches, and technology,” commented Mike McCully, CEO of Gate Neurosciences.
  • The Dreem™ 3S data flows into Beacon Biosignals' analytics platform to provide validated neurophysiological endpoints for clinical trials.

InFlectis BioScience Awarded $943,000 Grant from the ALS Association to Advance Ongoing ALS Clinical Trial with the Support of IRCCS Carlo Besta Neurological Institute

Retrieved on: 
Wednesday, January 3, 2024

The trial is investigating IFB-088 (INN: icerguastat), a multifunctional drug that modulates the PPP1R15A/PP1c phosphatase complex and inhibits NR2B-containing NMDAR.

Key Points: 
  • The trial is investigating IFB-088 (INN: icerguastat), a multifunctional drug that modulates the PPP1R15A/PP1c phosphatase complex and inhibits NR2B-containing NMDAR.
  • The potential of IFB-088 lies in its ability to target three major ALS cellular pathophysiological mechanisms to manage disease progression: protein aggregation, oxidative stress, and glutamate excitotoxicity.
  • InFlectis Bioscience has been awarded a $943K grant from the ALS Association to support the recruitment of 50 patients by the end of January 2024 for its Phase 2 clinical trial evaluating IFB-088.
  • The grant also supports a multi-omics approach, conducted by the IRCCS "Carlo Besta" Neurological Institute in Milan, Italy to investigate pharmacodynamic biomarker candidates, which will be useful in a future pivotal clinical study.

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Retrieved on: 
Wednesday, December 27, 2023

The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.

Key Points: 
  • The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.
  • In the study, AV-101 prodrug was systematically administered in four rat models of pain to examine its analgesic and behavioral profile.
  • The preclinical study was conducted by Tony L. Yaksh, PhD, Professor of Anesthesiology and Pharmacology at the University of California, San Diego.
  • Vistagen plans to seek potential strategic collaborations to further advance the clinical development and commercialization of AV-101.

Arialys Therapeutics Launches to Lead the Development of New Precision Medicines for Autoimmune Neuropsychiatric Diseases

Retrieved on: 
Tuesday, September 12, 2023

Arialys Therapeutics , a biotechnology company pioneering new therapeutics for autoimmune neuropsychiatry, today announced the close of $58 million in seed financing.

Key Points: 
  • Arialys Therapeutics , a biotechnology company pioneering new therapeutics for autoimmune neuropsychiatry, today announced the close of $58 million in seed financing.
  • The proceeds of the financing will be used to advance new precision medicines that specifically block pathogenic autoantibodies in the central nervous system (CNS) and meaningfully expand the treatment possibilities for neuropsychiatric diseases driven by autoimmunity.
  • “Recent scientific discoveries have implicated abnormal autoimmune activity in a number of neuropsychiatric diseases, pointing us in a new direction to develop precision medicines for CNS disorders,” said Jay Lichter, PhD, President and CEO of Arialys and Managing Partner of Avalon BioVentures.
  • Arialys has received orphan drug designation from the U.S. Food and Drug Administration for ART5803 for the treatment of ANRE.

Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

Retrieved on: 
Thursday, July 13, 2023

AV-101 is the Company’s oral prodrug antagonist at the NMDAR (N-methyl-D-aspartate receptor) glycine site.

Key Points: 
  • AV-101 is the Company’s oral prodrug antagonist at the NMDAR (N-methyl-D-aspartate receptor) glycine site.
  • The patent, once granted, will not expire until at least 2034.
  • The U.S. Patent and Trademark Office (USPTO) granted a related U.S. patent for Vistagen’s AV-101 and similar patents have been granted or are pending in several additional major pharmaceutical markets.
  • The study demonstrated that AV-101 significantly (p = 0.01) reduced LID without affecting the timing, extent, or duration of the therapeutic benefits of L-Dopa.

Gate Neurosciences Hones in on Precision Medicine with Expanded Research Operations Supporting Its Synaptic Function-Enhancing Molecules

Retrieved on: 
Wednesday, May 3, 2023

Gate Neurosciences, a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced it has increased its R&D capabilities with new expanded research operations and lab facilities in Evanston, Illinois.

Key Points: 
  • Gate Neurosciences, a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced it has increased its R&D capabilities with new expanded research operations and lab facilities in Evanston, Illinois.
  • There, Gate will further build the translational biomarker data package supporting its NMDA receptor modulator portfolio and advance foundational mechanism insights behind its synaptic function-enhancing molecules.
  • The expanded research supports parallel clinical development of the “stinel” class including lead oral program zelquistinel in Phase 2 for major depressive disorder (MDD).
  • Gate Neuro has expanded its R&D operations with new lab facilities located in Evanston, IL including nearly 2,000 sq.

Vistagen Receives New European Patent for AV-101

Retrieved on: 
Thursday, April 6, 2023

Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) has granted the Company a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist.

Key Points: 
  • Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) has granted the Company a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist.
  • The patent relates to the synthesis of AV-101 and certain chemical intermediaries, which synthesis yields AV-101 in commercial quantities and has the scalability for commercial manufacture.
  • The new European patent is a counterpart to previously granted U.S. patent 11,427,530 and will be in effect until at least 2039.
  • “Expanding our patent portfolio for all of our product candidates is an ongoing priority to support our global development and commercialization strategies across our pipeline,” said Shawn Singh, Chief Executive Officer of Vistagen.

EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury

Retrieved on: 
Wednesday, February 15, 2023

EuMentis is in active discussion with other investors to complete its Series B round.

Key Points: 
  • EuMentis is in active discussion with other investors to complete its Series B round.
  • The complete Series B financing will enable EuMentis to conduct an additional randomized, placebo-controlled Phase 2 clinical trial of EM-221, its best-in-class PDE10A inhibitor, in TS patients.
  • We believe that EuMentis’ novel therapies have the potential to dramatically improve the quality of life of patients suffering from autism, Tourette syndrome and traumatic brain injury, and other serious neuropsychiatric and neurodevelopment conditions.
  • We likewise look forward to advancing EM-221 into a randomized, placebo-controlled Phase 2 clinical study for Tourette syndrome with additional Series B capital.”

EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury

Retrieved on: 
Wednesday, February 8, 2023

A key scientific focus of EuMentis is to advance novel fast-off NMDAR antagonists to block signaling of over-active glutamate receptors in order to restore glutamate balance across diseases and indications, including TBI.

Key Points: 
  • A key scientific focus of EuMentis is to advance novel fast-off NMDAR antagonists to block signaling of over-active glutamate receptors in order to restore glutamate balance across diseases and indications, including TBI.
  • Once the preclinical study is completed, EuMentis plans to advance the selected lead candidate into a Phase I clinical trial in 2024.
  • To date, EuMentis has received over $11 million in funding from private and government sources to support research and development of its broad pipeline of novel CNS-based therapeutics.
  • “Currently there are no approved therapeutics for traumatic brain injury, which impact hundreds of thousands of Americans annually and leads to significant disability and death.

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

Retrieved on: 
Wednesday, December 7, 2022

CORAL GABLES, Fla., Dec. 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced results of the RELIANCE I study (REL-1017-301), evaluating REL-1017 as an adjunctive treatment for Major Depressive Disorder (MDD).  The same factors that negatively affected the previously announced results from the RELIANCE III study, a limited number of high enrolling sites with unplausible placebo response, also affected RELIANCE I and the study did not achieve its primary endpoint, which was a statistically significant improvement in depression symptoms compared to placebo as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) on Day 28.  RELIANCE I evaluated the use of REL-1017 in addition to a standard antidepressant for patients who had inadequate response to at least one and up to three standard antidepressant therapies.

Key Points: 
  • REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
  • In a Phase 2 trial, REL-1017 demonstrated rapid, robust, and sustained antidepressant effects with statistically significant improvements compared to placebo.
  • Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD).
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.